Assets Held for Sale	3 Months Ended
Mar. 31, 2026
Discontinued Operations and Disposal Groups [Abstract]
Assets Held for Sale	Assets Held for Sale In connection with the 2025 restructuring activities discussed in Note 14 “Restructuring and Other Charges,” during the third quarter of 2025, we committed to a plan to sell a manufacturing facility, including land, building and building improvements (collectively the “disposal group”) in Juarez, Mexico. During the third quarter of 2025, we classified the disposal group as held for sale for $27.9 million and recognized an impairment loss of $23.1 million, which was recorded within Cost of net revenues and attributable to our Clear Aligner reportable segment. As of December 31, 2025, we had assets held for sale of $28.0 million. During the first quarter of 2026, we recognized a gain of $11.7 million resulting from an increase in fair value less costs to sell, driven by updated market‑based information. The gain was recorded within Cost of net revenues in our Condensed Consolidated Statement of Operations and was attributable to our Clear Aligner reportable segment. As of March 31, 2026, we had assets held for sale of $39.8 million, which are presented separately as Assets held for sale in our Condensed Consolidated Balance Sheets.

Assets Held for Sale

3 Months Ended

Mar. 31, 2026

Discontinued Operations and Disposal Groups [Abstract]

In connection with the 2025 restructuring activities discussed in Note 14 “Restructuring and Other Charges,” during the third quarter of 2025, we committed to a plan to sell a manufacturing facility, including land, building and building improvements (collectively the “disposal group”) in Juarez, Mexico. During the third quarter of 2025, we classified the disposal group as held for sale for $27.9 million and recognized an impairment loss of $23.1 million, which was recorded within Cost of net revenues and attributable to our Clear Aligner reportable segment. As of December 31, 2025, we had assets held for sale of $28.0 million.

During the first quarter of 2026, we recognized a gain of $11.7 million resulting from an increase in fair value less costs to sell, driven by updated market‑based information. The gain was recorded within Cost of net revenues in our Condensed Consolidated Statement of Operations and was attributable to our Clear Aligner reportable segment. As of March 31, 2026, we had assets held for sale of $39.8 million, which are presented separately as Assets held for sale in our Condensed Consolidated Balance Sheets.